


eye-light®

From the front to the back of the eye,
an all-in-one powerhouse for eye care.



eye-light® utilizes advanced LM™ LLLT and OPE™ IPL technologies to provide optimal, **non-invasive treatments for both anterior and posterior segment conditions.**



With both LM™ LLLT (PBM) and OPE™ IPL it addresses anterior segment conditions such as **DED, MGD, Blepharitis, Chalazia,** and **Sjögren's Syndrome,** while with LM™ LLLT (PBM) is setting new standards in posterior segment conditions like **dry AMD** and beyond.

eye-light®

Anterior Segment Solutions.

eye-light®, our flagship solution for comprehensive anterior segment care, leverages our groundbreaking technologies, LM™ LLLT and OPE™ IPL*, to provide optimal, non-invasive treatment for a wide range of ocular surface conditions.

eye-light® is built with three elements: the device, from which the treatments get set, and the two terminals—one for OPE™ IPL* and one for LM™ LLLT.


LM™ LLLT in ophthalmology can be leveraged employing three different light frequencies—each with its own unique benefits and use cases.



LM™ LLLT RED

- > Improved cellular metabolism
- > Inflammation reduction
- > Transcription factor activation

Anterior Segment Applications:
DED/MGD, Chalazion, Sjögren's Syndrome, Blepharitis, Cataract & Refractive Surgery-induced DED



LM™ LLLT BLUE

- > Enhanced photosensitization process
- > Microbiome stabilization
- > Antibacterial action
- > Singlet oxygen production

Anterior Segment Applications:
Demodex, Blepharitis, Rosacea



LM™ LLLT YELLOW

- > Enhanced ATP production
- > Nitric Oxide release facilitation
- > Inflammation & edema reduction

Anterior Segment Applications:
Post-Blepharoplasty

OPE™ IPL* is our patented Intense Pulsed Light technology, calibrated for optimal safety and effectiveness through software-controlled thermal impulses.



OPE™ IPL

- > Improves blood circulation by dissipating blood vessels
- > Enhances anti-inflammatory cytokines secretion

Ophthalmology Use:
DED/MGD, Blepharitis, Rosacea, Sjögren's Syndrome


* Available only for Anterior Segment use.

eye-light®

Posterior Segment Solutions.

eye-light®, with its patented Light Modulation™ LLLT technology, is the most optimized and disruptive light-based solution for the management of posterior segment conditions.

eye-light® is built with three elements: the device, from which the treatments get set, and the two LM™ LLLT masks – Red and Yellow – both needed to treat dAMD and other retinal conditions.



As age advances, AMD worsens due to increased ROS, damaging the retina. Mitochondria, the primary ROS source, are crucial.

PBM targets mitochondrial dysfunction, boosting ATP and reducing oxidative stress, slowing AMD progression and supporting retinal health.



LM™ LLLT (PBM) YELLOW

Yellow light (590 nm) naturally inhibits VEGF expression, reducing blood vessel formation linked to wet AMD.

- > Oxydative Stress Reduction
- > VEGF Inhibition
- > Oedema Reduction & Drainage

① Visual Acuity
Improvement

② Contrast Sensitivity
Improvement



LM™ LLLT (PBM) RED

Red light (630 nm) boosts ATP production, restores mitochondria and increases metabolic activity, inhibits inflammation and cell death.

- > HIF-1α Factor Stimulus
- > Inflammatory Biomarkers Reduction
- > ATP Stimulus

③ Central Drusen Volume
Reduction

④ Completely Painless
Therapy

SCIENTIFIC COVERAGE > ANTERIOR SEGMENT



G. GIANNACCARE


Italy
MD, PHD, FEBO

GIANNACCARE, Giuseppe et al. Outcomes of LLLT for the prophylaxis of Iatrogenic Dry Eye after Cataract Surgery: A Prospective Randomized Double-Masked Controlled Clinical Trial. British Journal of Ophthalmology, May 2023.


LEGEND ■ LLLT ■ CONTROL

Results

OSDI > LOW IS BETTER




NIBUT > HIGHER IS BETTER



Protocols


SAMPLE




A. MEDURI

Italy
MD, PHD

Meduri A., Oliverio G. W., Tedesco G., Aragona P. Combined intense pulsed light and low level light therapy for the treatment of refractory Meibomian gland dysfunction. European Journal of Ophthalmology, August 2022.



LEGEND ■ LLLT + IPL ■ CONTROL [Eye Drops]



SCIENTIFIC COVERAGE
> POSTERIOR SEGMENT

We are **pioneering** what's next in **retinal care**, drawing insights from large-scale, global, multi-centric studies like **LightWave I & II**.

LightWave I


> SELECTED CASE REPORTS



↓ DOWNLOAD
LIGHTWAVE I
CLINICAL TRIAL
PRESS RELEASE
[Press Release](#)


CASE #1 > 68 Y/O FEMALE

Dry AMD, Age-Related Eye Disease Study (AREDS) grade 3
T₀ BCVA: 50 ETDRS
T₁ BCVA: 55 ETDRS letters



CASE #2 > 72 Y/O FEMALE

Dry AMD, Age-Related Eye Disease Study (AREDS) grade 3
T₀ BCVA: 52 ETDRS
T₁ BCVA: 56 ETDRS letters



Some examples from LightWave I clinical trial about the results obtained with our photobiomodulation therapy.



↗ APPLY & JOIN
LIGHTWAVE II
CLINICAL TRIALS
[Press Release](#)



↗ JOIN US
AT THE FOREFRONT
INNOVATION:
SCIENTIFIC COMMUNITY
[Join Now!](#)



Visit our **Scientific Community** to connect and grow with fellow innovators.